Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)(COMPLETED)
Information source: Schering-Plough
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infection, Invasive Fungal
Phase: N/A
Status: Completed
Sponsored by: Schering-Plough
Summary
This retrospective study is designed to provide a consistent method of screening and
collecting data on patients who will serve as controls for a comparison of the efficacy of
the available antifungal therapies used as salvage treatments for patients with refractory
IFI or for patients with refractory IFI or for patients with IFI who are intolerant to
standard antifungal therapies.
Clinical Details
Official title: A Retrospective Study to Establish an Historical Database on the Efficacy of Standard Antifungal Therapy in Patients With Invasive Fungal Infections
Study design: Natural History, Cross-Sectional, Defined Population, Retrospective Study
Detailed description:
The current clinical trial is designed to provide historicals controls comparable to the
P00041 study population, that is, a) patients with invasive fungal infections which are
refractory or resistant to standard antifungal therapies or b) patients who have developed
intolerance to standard antifungal therapy. This clinical trial also serves to allow
collection of historical data regarding the efficacy of available antifungal therapies
against a variety of invasive fungal infections which although serious and life-threatening
are sufficiently rare so that they cannot be studied in a controlled, randomized clinical
trial.
This trial will be conducted primarily at the investigative sites that enrolled subjects into
P00041 and/or investigators who are members of the Mycosis Study Group.
Eligibility
Minimum age: 13 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males and females of any race greater than or equal to 13 years of age
- Treatment for an IFI between April 30, 1996 and April 30, 2001 at one of the centers
participating in P00041 or at other non-P00041 centers
- A diagnosis of proven or probable IFI based on MSG/EORTC criteria
- Refractory IFI or intolerence to standard therapy
The date of diagnosis of an IFI will be the earliest date on which one or more of the
following diagnostic procedures used to establish the diagnosis was performed:
- Fungal culture, histopathology, bronchoscopy, and autopsy report
- X-Rays, CT scan, MRI, ultrasound, and bone scan
- Serology
Exclusion Criteria:
1. Female subject who was pregnant or nursing at the time IFI was diagnosed
2. Hepatic function tests: ALT or AST greater than 10 times the upper limit of normal at
the time IFI was diagnosed
3. Enrollment in P00041 for treatment of the IFI
4. Patient with sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis
5. Patients with chronic invasive aspergillosis (chronic necrotizing pulmonary
aspergillosis)
6. Patients with diagnosis of CMV pneumonia
7. Patients with a diagnosis of pulmonary tuberculosis
8. Death within 72 hours of the start of antifungal therapy
9. Patients on artificial ventilation, who were not extubated within 24 hours of
commencing standard antifungal therapy
Locations and Contacts
Additional Information
Starting date: October 2001
Last updated: May 31, 2006
|